| Inflammatory bowel disease: clinical aspects and treatments M Fakhoury, R Negrulj, A Mooranian, H Al-Salami Journal of inflammation research, 113-120, 2014 | 574 | 2014 |
| Microparticles, microcapsules and microspheres: a review of recent developments and prospects for oral delivery of insulin CY Wong, H Al-Salami, CR Dass International journal of pharmaceutics 537 (1-2), 223-244, 2018 | 241 | 2018 |
| Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles N Pavlović, S Goločorbin-Kon, M Ðanić, B Stanimirov, H Al-Salami, ... Frontiers in Pharmacology 9, 411880, 2018 | 213 | 2018 |
| Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment CY Wong, H Al-Salami, CR Dass Journal of controlled release 264, 247-275, 2017 | 209 | 2017 |
| Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats H Al-Salami, G Butt, JP Fawcett, IG Tucker, S Golocorbin-Kon, M Mikov European journal of drug metabolism and pharmacokinetics 33, 101-106, 2008 | 172 | 2008 |
| Oral insulin delivery: existing barriers and current counter-strategies A Gedawy, J Martinez, H Al-Salami, CR Dass Journal of pharmacy and pharmacology 70 (2), 197-213, 2018 | 137 | 2018 |
| Blood-brain barrier dysfunction precedes cognitive decline and neurodegeneration in diabetic insulin resistant mouse model: an implication for causal link R Takechi, V Lam, E Brook, C Giles, N Fimognari, A Mooranian, ... Frontiers in aging neuroscience 9, 399, 2017 | 133 | 2017 |
| Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome M Ðanić, B Stanimirov, N Pavlović, S Goločorbin-Kon, H Al-Salami, ... Frontiers in pharmacology 9, 401908, 2018 | 116 | 2018 |
| A systematic review of the valproic-acid-induced rodent model of autism D Chaliha, M Albrecht, M Vaccarezza, R Takechi, V Lam, H Al-Salami, ... Developmental neuroscience 42 (1), 12-48, 2020 | 98 | 2020 |
| The influence of intestinal tract and probiotics on the fate of orally administered drugs M Stojančević, G Bojić, H Al Salami, M Mikov Current issues in molecular biology 16 (1), 55-68, 2014 | 98 | 2014 |
| Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus CY Wong, H Al-Salami, CR Dass International journal of pharmaceutics 549 (1-2), 201-217, 2018 | 90 | 2018 |
| Molecular mechanism of action and pharmacokinetic properties of methotrexate V Maksimovic, Z Pavlovic-Popovic, S Vukmirovic, J Cvejic, A Mooranian, ... Molecular biology reports 47, 4699-4708, 2020 | 87 | 2020 |
| Development and validation of a new analytical HPLC method for simultaneous determination of the antidiabetic drugs, metformin and gliclazide A Gedawy, H Al-Salami, CR Dass journal of food and drug analysis 27 (1), 315-322, 2019 | 81 | 2019 |
| Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol A Mooranian, R Negrulj, N Chen-Tan, HS Al-Sallami, Z Fang, TK Mukkur, ... Drug design, development and therapy, 1221-1230, 2014 | 77 | 2014 |
| C2C12 cell model: its role in understanding of insulin resistance at the molecular level and pharmaceutical development at the preclinical stage CY Wong, H Al-Salami, CR Dass Journal of Pharmacy and Pharmacology 72 (12), 1667-1693, 2020 | 75 | 2020 |
| Probiotic Pre‐treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats H Al‐Salami, G Butt, I Tucker, R Skrbic, S Golocorbin‐Kon, M Mikov Archives of drug information 1 (1), 35-41, 2008 | 75 | 2008 |
| Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. H Al-Salami, G Butt, I Tucker, M Mikov Methods and findings in experimental and clinical pharmacology 30 (2), 107-113, 2008 | 75 | 2008 |
| Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of … A Mooranian, R Negrulj, S Mathavan, J Martinez, J Sciarretta, ... Journal of Pharmaceutical Innovation 9, 150-157, 2014 | 73 | 2014 |
| An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations A Mooranian, R Negrulj, S Mathavan, J Martinez, J Sciarretta, ... Pharmaceutical development and technology 20 (6), 702-709, 2015 | 67 | 2015 |
| Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells A Mooranian, R Negrulj, F Arfuso, H Al-Salami Artificial cells, nanomedicine, and biotechnology 44 (1), 194-200, 2016 | 62 | 2016 |
Dr Armin MooranianLecturer of Pharmacy and Pharmaceutical SciencesVerified email at curtin.edu.au
